Gilead Sciences Inc.

Company Snapshot

Founded: 1987

Entity Type: Public

Employees: 17,600

Region: U.S.

Revenue: $28,754.0 Millions

Revenue Year: 2024

Segment: Cell Therapy

Headquarter: Foster City, California, U.S.

Key Geographics: U.S., Europe

Corporate Address: 333 Lakeside Drive, Foster City, California 94404, U.S. Tel. +1-650-574-3000 www.gilead.com

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company offering medicines for HIV, viral hepatitis, COVID-19, and cancer. The company operates in a single business segment that focuses on discovering, developing, and commercializing innovative medicines in areas of unmet medical need. Gilead Sciences, Inc. offers several blockbuster drugs for the prevention and treatment of HIV, including Biktarvy, Genvoya, Descovy, and Odefsey. The cancer portfolio includes cell therapies (Yescarta and Tecartus) and ADC (Trodelvy). 2020 Gilead Sciences, Inc. acquired Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed ADC, by acquiring Immunomedics for approximately $21.0 billion deal value.

Financial Highlights (FY 2024)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Gilead Sciences Inc. In Reports

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

According to BCC Research detailed report on Genetic Modification Therapies Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration

According to BCC Research detailed report on advanced drug delivery systems market estimates, data will be provided for 2024 because of the base year, with forecasts for 2025 and forecast value for 2030.

Immunotherapy Drugs: Global Markets

Our Research report provides an overview of the immunotherapy drugs market report analyzes the market trends of immunotherapy drugs with data from 2024, estimates from 2025, projections of compound annual growth rates...

View All Reports

Gilead Sciences Inc. In News

Gilead Names Wettan Executive Vice President - BioXconomy

BioXconomy - Jan 08, 2026

Gilead Names Wettan Executive Vice President - BioXconomy

BioXconomy - Jan 08, 2026

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Yahoo Finance - Jan 05, 2026

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate - BioSpace

BioSpace - Jan 06, 2026

Read All News

Company's Business Segments

HIV : Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Truvada, Stribild, Sunlenca, Veklury, Epclusa, Vemlidy, Harvon, Viread
Oncology : Yescarta, Trodelvy, Tecartus
Liver Disease : Ledipasvir/ Sofosbuvi, Sofosbuvir/Velpatasvir, Other HCV, Vemlidy, Viread, Other HBV/HDV
Veklury : Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor
Other : AmBisome, Letairis, Royalty, contract and other revenues

Applications/End User Industries

Theapeutic Area
Medicines
Pipeline

Research
Clinical Trials
Pharmaceutical Companies

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment